Figure 1.

EPDBi for screening the ERG/EBS-WT binding inhibitors. EPDBi was performed on streptavidin-coated plates in which biotinylated EBS-WT oligonucleotides were fixed. ERG proteins were added together with the indicated DB compounds at 5 µM. Control corresponds to 100% of ERG/DNA complex. EBS-WT DNA-binding specificity was validated by addition of 50-fold excess of EBS-WT (50× S) or non-specific oligonucleotide (50× NS) in the binding buffer. Results are means ± s.e.m. from two experiments both performed in triplicate.